Alnylam Pharmaceuticals Inc (ALNY)
244.89
-1.91
(-0.77%)
USD |
NASDAQ |
Nov 22, 16:00
246.38
+1.49
(+0.61%)
After-Hours: 20:00
Alnylam Pharmaceuticals Cash from Operations (Quarterly): 43.71M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 43.71M |
June 30, 2024 | 124.16M |
March 31, 2024 | -81.52M |
December 31, 2023 | -29.80M |
September 30, 2023 | 359.41M |
June 30, 2023 | -58.99M |
March 31, 2023 | -166.48M |
December 31, 2022 | -131.98M |
September 30, 2022 | -115.28M |
June 30, 2022 | -122.82M |
March 31, 2022 | -171.19M |
December 31, 2021 | -150.14M |
September 30, 2021 | -134.04M |
June 30, 2021 | -121.86M |
March 31, 2021 | -235.66M |
December 31, 2020 | -123.14M |
September 30, 2020 | -110.33M |
June 30, 2020 | -135.33M |
March 31, 2020 | -246.16M |
December 31, 2019 | -195.98M |
September 30, 2019 | -182.63M |
June 30, 2019 | 288.70M |
March 31, 2019 | -188.51M |
December 31, 2018 | -150.46M |
September 30, 2018 | -153.81M |
Date | Value |
---|---|
June 30, 2018 | -102.69M |
March 31, 2018 | -155.66M |
December 31, 2017 | -103.04M |
September 30, 2017 | -98.36M |
June 30, 2017 | -81.05M |
March 31, 2017 | -100.33M |
December 31, 2016 | -78.34M |
September 30, 2016 | -75.54M |
June 30, 2016 | -70.20M |
March 31, 2016 | -83.62M |
December 31, 2015 | -53.06M |
September 30, 2015 | -54.36M |
June 30, 2015 | -55.46M |
March 31, 2015 | -26.26M |
December 31, 2014 | -36.64M |
September 30, 2014 | -40.71M |
June 30, 2014 | -46.62M |
March 31, 2014 | -41.68M |
December 31, 2013 | -22.37M |
September 30, 2013 | -21.72M |
June 30, 2013 | -23.60M |
March 31, 2013 | -0.971M |
December 31, 2012 | -68.91M |
September 30, 2012 | 5.212M |
June 30, 2012 | -21.69M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-246.16M
Minimum
Mar 2020
359.41M
Maximum
Sep 2023
-90.17M
Average
-122.98M
Median
Cash from Operations (Quarterly) Benchmarks
Pfizer Inc | 6.714B |
BridgeBio Pharma Inc | -180.57M |
Gilead Sciences Inc | 4.309B |
Johnson & Johnson | 7.993B |
Biomarin Pharmaceutical Inc | 221.48M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -30.25M |
Cash from Financing (Quarterly) | 102.76M |
Free Cash Flow | 16.06M |
Free Cash Flow Per Share (Quarterly) | 0.3073 |
Free Cash Flow to Equity (Quarterly) | 38.55M |
Free Cash Flow to Firm (Quarterly) | 41.80M |
Free Cash Flow Yield | 0.05% |